Nevada
|
000-54014
|
20-5093315
|
(State or other jurisdiction of
incorporation) |
(Commission File Number)
|
(IRS Employer
Identification Number) |
343 Allerton Ave.
South San Francisco, California 94090
|
(Address of principal executive offices)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
VTGN
|
Nasdaq Capital Market
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
For
|
Against
|
Abstain
|
|||||||
Votes
|
104,229,120
|
25,372,666
|
4,016,453
|
For
|
Against
|
Abstain
|
|||||||
Votes
|
65,592,186
|
24,302,176
|
3,454,611
|
Vistagen Therapeutics, Inc.
|
||
|
|
|
Date: October 28, 2022
|
By:
|
/s/ Shawn K. Singh
|
|
|
Shawn K. Singh
Chief Executive Officer
|